

If there are any additional fees required as a result of the submission and amendments made in this response, the Commissioner is hereby authorized to debit our Deposit Account No. 08-3255.

Please enter the following submissions:

IN THE ABSTRACT

No changes.

IN THE DISCLOSURE

No changes.

IN THE CLAIMS

Please amend the following claims.

1. (Amended) A [co-precipitate] composition comprising a co-precipitate of cefuroxime axetil and a water-soluble excipient.
2. (Amended) [A co-precipitate as in] The composition of claim 1 comprising from about 40% to about 98% by weight cefuroxime axetil and from about 2% to about 60% by weight water-soluble excipient.
3. (Amended) [A co-precipitate as in] The composition of claim 1 comprising from about 75% to about 95% by weight cefuroxime axetil and from about 5% to about 25% by weight water-soluble excipient.

4. (Amended) [A co-precipitate as in] The composition of claim 1 comprising about 90% by weight cefuroxime axetil and about 10% by weight water-soluble excipient.
5. (Amended) [A co-precipitate as in] The composition of claim 1 wherein the water-soluble excipient is selected from the group consisting of povidone, hydroxy propyl cellulose, methycellulose, lactose, mannitol and sorbitol.
6. (Amended) A process of production of [a co-precipitate] the composition of claim 1 which comprises:
 - dissolving the cefuroxime axetil and water-soluble excipient in a solvent or a mixture of solvents; and
 - evaporating the solvent or solvents.
7. (Amended) [A] The process [as in] of claim 6 wherein acetone is used as solvent.
8. (Amended) [A] The process [as in] of claim 6 wherein the solvent or solvents are evaporated by spray-drying.
9. (Amended) A pharmaceutical tablet comprising [a co-precipitate] the composition according to claim 1.
10. (Amended) [A] The pharmaceutical tablet [as in] of claim 9 further comprising a disintegrant.
11. (Amended) [A] The pharmaceutical tablet [as in] of claim 10 wherein the disintegrant is a water-insoluble cross-linked polymer.

12. (Amended) [A] The pharmaceutical tablet [as in] of claim 10 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate and crospovidone.
13. (Amended) [A] The pharmaceutical tablet [as in] of claim 10 further comprising a lubricant.
14. (Amended) [A] The pharmaceutical tablet [as in] of claim 13 wherein the lubricant is stearic acid or a metallic stearate.

Please add the following claims. Since Applicant is allowed 3 independent claims and 17 dependent claims, Applicant believes that the base filing fee covers the additional claims set out below. Therefore no additional fees are required for the additional claims 15 to 20.

15. A composition comprising a co-precipitate of cefuroxime axetil and sorbital.
16. The composition of claim 15 comprising about 90% cefuroxime axetil and about 10% sorbital.
17. A process of production of the composition of claim 15 which comprises:
 - dissolving the cefuroxime axetil and sorbital in a solvent or a mixture of solvents; and
 - evaporating the solvent or solvents.
18. The process of claim 16 wherein acetone is used as solvent.
19. A pharmaceutical tablet comprising the composition according to claim 15.